Korean J Otorhinolaryngol-Head Neck Surg.  2010 Apr;53(4):203-208. 10.3342/kjorl-hns.2010.53.4.203.

Combinatorial Targeted Therapy in Thyroid Cancer

• Koh YW

• KMID: 1455685
• DOI: http://doi.org/10.3342/kjorl-hns.2010.53.4.203

Abstract

The elucidation of the signal-transduction pathways that drive neoplastic transformation has led to novel rationally designed cancer therapeutics (targeted therapy). Several compounds directed against different molecular pathways are being tested in patients with advanced thyroid carcinoma. Anticancer drugs that target protein kinases include small molecule inhibitors and monoclonal antibodies. Feedback loops and cross talk between signaling pathways impact significantly on the efficacy of cancer therapeutics, and resistance to targeted agents is a major barrier to effective treatments. Increasingly, therapies are being designed to target multiple kinase pathways. This can be achieved using a single agent that inhibits multiple signaling pathways or a combination of highly selective agents. In this review we discuss the principles of specifically targeting multiple kinase pathways with particular reference to targeted therapy for thyroid cancer.

Keyword

Targeted therapy; Protein kinase; Feedback loops; Thyroid cancer

MeSH Terms

Antibodies, Monoclonal
Humans
Phosphotransferases
Protein Kinases
Thyroid Gland
Thyroid Neoplasms
Antibodies, Monoclonal
Phosphotransferases
Protein Kinases